MARCHICA, VALENTINA
 Distribuzione geografica
Continente #
EU - Europa 1.244
NA - Nord America 1.215
AS - Asia 411
Continente sconosciuto - Info sul continente non disponibili 6
AF - Africa 5
OC - Oceania 1
Totale 2.882
Nazione #
US - Stati Uniti d'America 1.199
IE - Irlanda 327
CN - Cina 304
SE - Svezia 290
IT - Italia 241
AT - Austria 135
DE - Germania 82
TR - Turchia 68
FI - Finlandia 57
BE - Belgio 29
RO - Romania 20
CA - Canada 15
IN - India 15
SG - Singapore 14
FR - Francia 13
GB - Regno Unito 11
NL - Olanda 8
UA - Ucraina 7
EU - Europa 6
ES - Italia 5
RU - Federazione Russa 4
BG - Bulgaria 3
CZ - Repubblica Ceca 3
IR - Iran 3
LU - Lussemburgo 3
SC - Seychelles 3
IL - Israele 2
KH - Cambogia 2
NG - Nigeria 2
SM - San Marino 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
BN - Brunei Darussalam 1
BZ - Belize 1
CH - Svizzera 1
DK - Danimarca 1
HK - Hong Kong 1
MD - Moldavia 1
RS - Serbia 1
Totale 2.882
Città #
Chandler 333
Dublin 324
Vienna 111
Parma 110
Ashburn 104
Ann Arbor 93
Dearborn 67
New York 57
Izmir 54
Shanghai 54
Nanjing 51
Beijing 46
Princeton 45
Brussels 29
Wilmington 27
Bremen 23
Shenyang 23
Helsinki 22
San Mateo 15
Hebei 14
Jinan 13
Kunming 13
Nanchang 13
Kocaeli 12
Focsani 10
Milan 10
Modena 10
Redmond 10
Fairfield 8
Houston 8
Jiaxing 8
Toronto 8
Woodbridge 8
Changsha 7
Hefei 7
Norwalk 7
Bologna 6
Guangzhou 6
Pune 6
Savignano sul Rubicone 6
Tianjin 6
Zhengzhou 6
Boardman 5
Des Moines 5
Düsseldorf 5
Hangzhou 5
Jacksonville 5
Madrid 5
Palermo 5
Rho 5
Seattle 5
Washington 5
Rio Saliceto 4
Romainville 4
Torino 4
Ahmedabad 3
Cesena 3
Fremont 3
Gorgonzola 3
London 3
Lviv 3
Nürnberg 3
Ottawa 3
Redwood City 3
Reggio Emilia 3
San Giuliano Milanese 3
Sofia 3
St Louis 3
Amsterdam 2
Arcevia 2
Borås 2
Cento 2
Chengdu 2
Cornaredo 2
Edinburgh 2
Florence 2
Grafing 2
Lagos 2
Luxembourg 2
Manchester 2
Montreal 2
Phnom Penh 2
Piacenza 2
Pilastro 2
Rome 2
Sabz 2
Taiyuan 2
Taizhou 2
Tampa 2
Tel Aviv 2
Turin 2
Turku 2
Vignola 2
Xian 2
Ankara 1
Atlanta 1
Augusta 1
Bandar Seri Begawan 1
Belgrade 1
Belize City 1
Totale 1.949
Nome #
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 93
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 93
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 90
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 88
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 88
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 88
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 86
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 86
A simplified sars-cov-2 pseudovirus neutralization assay 84
Possible targets to treat myeloma-related osteoclastogenesis 81
Novel targets for the treatment of relapsing multiple myeloma 81
Oncolytic virotherapy and microenvironment in multiple myeloma 76
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 75
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 74
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 71
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 70
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 68
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 68
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 65
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 64
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 64
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 63
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 60
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 60
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 60
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 57
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 57
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 56
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma 55
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 55
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 53
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 53
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy 52
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 51
Concomitant primary hyperparathyroidism in patients with multiple myeloma: A possible link? 50
Role of Galectins in Multiple Myeloma. 49
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 49
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 49
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 48
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 48
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 46
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 44
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 43
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 38
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 38
The impact of CD56 expression in smoldering myeloma patients on early progression 28
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 23
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 20
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 17
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4) 16
Totale 2.991
Categoria #
all - tutte 10.182
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.182


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201992 0 0 0 0 0 0 0 0 7 10 71 4
2019/2020350 77 56 8 8 13 58 46 8 24 36 10 6
2020/2021250 30 4 7 7 40 8 15 22 44 28 16 29
2021/2022296 6 10 10 23 6 7 43 35 26 15 19 96
2022/20231.353 129 141 92 100 102 137 69 88 386 21 60 28
2023/2024403 33 47 20 21 39 160 49 11 23 0 0 0
Totale 2.991